Barclays Maintains Overweight on RXO, Raises Price Target to $20

RXO, Inc. Common Stock

RXO, Inc. Common Stock

RXO

0.00

Barclays analyst Brandon Oglenski maintains RXO (NYSE: RXO) with a Overweight and raises the price target from $17 to $20.